JP2025502816A - 希少バリアント多遺伝子リスクスコア - Google Patents

希少バリアント多遺伝子リスクスコア Download PDF

Info

Publication number
JP2025502816A
JP2025502816A JP2024539696A JP2024539696A JP2025502816A JP 2025502816 A JP2025502816 A JP 2025502816A JP 2024539696 A JP2024539696 A JP 2024539696A JP 2024539696 A JP2024539696 A JP 2024539696A JP 2025502816 A JP2025502816 A JP 2025502816A
Authority
JP
Japan
Prior art keywords
rare
variant
computer
variants
implemented method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024539696A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502816A5 (cg-RX-API-DMAC7.html
Inventor
ペトコ・プラメノフ・フィジエフ
ジェレミー・フランシス・マクレー
カイ-ハウ・ファー
Original Assignee
イルミナ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イルミナ インコーポレイテッド filed Critical イルミナ インコーポレイテッド
Priority claimed from PCT/US2022/054194 external-priority patent/WO2023129621A1/en
Publication of JP2025502816A publication Critical patent/JP2025502816A/ja
Publication of JP2025502816A5 publication Critical patent/JP2025502816A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/10—Boolean models
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Chemical & Material Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Databases & Information Systems (AREA)
  • Primary Health Care (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Software Systems (AREA)
  • Artificial Intelligence (AREA)
  • Evolutionary Computation (AREA)
  • Pathology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Ecology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
JP2024539696A 2021-12-29 2022-12-28 希少バリアント多遺伝子リスクスコア Pending JP2025502816A (ja)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US202163294816P 2021-12-29 2021-12-29
US202163294828P 2021-12-29 2021-12-29
US202163294827P 2021-12-29 2021-12-29
US202163294820P 2021-12-29 2021-12-29
US202163294813P 2021-12-29 2021-12-29
US202163294830P 2021-12-29 2021-12-29
US63/294,827 2021-12-29
US63/294,813 2021-12-29
US63/294,820 2021-12-29
US63/294,816 2021-12-29
US63/294,830 2021-12-29
US63/294,828 2021-12-29
US202263351283P 2022-06-10 2022-06-10
US202263351299P 2022-06-10 2022-06-10
US202263351317P 2022-06-10 2022-06-10
US63/351,299 2022-06-10
US63/351,283 2022-06-10
US63/351,317 2022-06-10
US17/968,723 US20230207052A1 (en) 2021-12-29 2022-10-18 Rare variant polygenic risk scores
US17/968,723 2022-10-18
PCT/US2022/054194 WO2023129621A1 (en) 2021-12-29 2022-12-28 Rare variant polygenic risk scores

Publications (2)

Publication Number Publication Date
JP2025502816A true JP2025502816A (ja) 2025-01-28
JP2025502816A5 JP2025502816A5 (cg-RX-API-DMAC7.html) 2025-12-23

Family

ID=86896998

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2024539696A Pending JP2025502816A (ja) 2021-12-29 2022-12-28 希少バリアント多遺伝子リスクスコア
JP2024539698A Pending JP2025502818A (ja) 2021-12-29 2022-12-28 キャリアと非キャリアとの間の分離を最大化する入れ子型t検定に基づく最適化された総和検定
JP2024539697A Pending JP2025502817A (ja) 2021-12-29 2022-12-28 異なる薬物使用パターンについての表現型測定値からの時間的データに対する共変量補正

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024539698A Pending JP2025502818A (ja) 2021-12-29 2022-12-28 キャリアと非キャリアとの間の分離を最大化する入れ子型t検定に基づく最適化された総和検定
JP2024539697A Pending JP2025502817A (ja) 2021-12-29 2022-12-28 異なる薬物使用パターンについての表現型測定値からの時間的データに対する共変量補正

Country Status (7)

Country Link
US (3) US20230207132A1 (cg-RX-API-DMAC7.html)
EP (5) EP4457829B1 (cg-RX-API-DMAC7.html)
JP (3) JP2025502816A (cg-RX-API-DMAC7.html)
KR (3) KR20240124391A (cg-RX-API-DMAC7.html)
CN (3) CN118451511A (cg-RX-API-DMAC7.html)
AU (3) AU2022426690A1 (cg-RX-API-DMAC7.html)
CA (2) CA3242597A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120977385B (zh) * 2025-10-20 2026-02-06 浙江博圣生物技术股份有限公司 一种单基因遗传病致病突变的打分排序方法及系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1301633A1 (en) * 2000-07-21 2003-04-16 Althea Technologies, Inc. A systematic approach to mechanism-of-response analyses
WO2014110350A2 (en) * 2013-01-11 2014-07-17 Oslo Universitetssykehus Hf Systems and methods for identifying polymorphisms
CN111161799B (zh) * 2019-12-24 2023-12-15 大连海事大学 一种基于多组学数据获取多基因风险评分的方法及系统
WO2022020444A1 (en) * 2020-07-22 2022-01-27 Algen Biotechnologies, Inc. Methods and systems for determining drug effectiveness

Also Published As

Publication number Publication date
EP4457829C0 (en) 2026-02-04
CN118451511A (zh) 2024-08-06
EP4715828A2 (en) 2026-03-25
AU2022426690A1 (en) 2024-07-04
EP4457829B1 (en) 2026-02-04
US20230207052A1 (en) 2023-06-29
US20230207067A1 (en) 2023-06-29
KR20240131385A (ko) 2024-08-30
CN118451506A (zh) 2024-08-06
EP4457819A1 (en) 2024-11-06
KR20240124391A (ko) 2024-08-16
CN118475982A (zh) 2024-08-09
EP4742250A2 (en) 2026-05-13
EP4457818B1 (en) 2025-12-24
EP4457818C0 (en) 2025-12-24
JP2025502818A (ja) 2025-01-28
CA3242597A1 (en) 2025-02-26
US20230207132A1 (en) 2023-06-29
JP2025502817A (ja) 2025-01-28
AU2022429829A1 (en) 2024-07-04
EP4457818A1 (en) 2024-11-06
EP4457829A1 (en) 2024-11-06
EP4715828A3 (en) 2026-06-17
AU2022425376A1 (en) 2024-06-27
KR20240124390A (ko) 2024-08-16
CA3242710A1 (en) 2023-07-06
EP4742250A3 (en) 2026-07-22

Similar Documents

Publication Publication Date Title
CN110892484A (zh) 用于识别引起序列特异性错误(sse)的序列图案的基于深度学习的框架
WO2023129621A1 (en) Rare variant polygenic risk scores
Zawar et al. Variants of uncertain significance: At the crux of diagnostic odyssey
US20250218534A1 (en) Artificial intelligence-based epigenetics at base resolution
US20250201348A1 (en) Artificial intelligence-based detection of gene conservation and expression preservation at base resolution
EP4457829B1 (en) Covariate correction for temporal data from phenotype measurements for different drug usage patterns
Rahaie et al. DeepGenePrior: A deep learning model for prioritizing genes affected by copy number variants
US20240112751A1 (en) Copy number variation (cnv) breakpoint detection
US20230343413A1 (en) Protein structure-based protein language models
US20230108368A1 (en) Combined and transfer learning of a variant pathogenicity predictor using gapped and non-gapped protein samples
WO2023129622A1 (en) Covariate correction for temporal data from phenotype measurements for different drug usage patterns
WO2023129619A1 (en) Optimized burden test based on nested t-tests that maximize separation between carriers and non-carriers
Ozdemir et al. A deep ensemble encoder network method for improved polygenic risk score prediction
Hedges Bioinformatics of Human Genetic Disease Studies
Nahlawi Increasing the Discovery Power and Confidence Levels of Disease Association Studies: A Survey

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251212